“EXPERT RECOMMENDATIONS ON THE CLINICAL PRACTICE OF TREATING NMOSD WITH INEBILIZUMAB” RELEASED IN SHANGHAI
Recently, the 4th Annual Academic Meeting of the Shanghai Stroke Association and the 17th Chinese Neurology Forum were held in Shanghai, where the “Expert Recommendations on the Clinical Practice of Treating Neuromyelitis Optica Spectrum Disorders With Inebilizumab” (hereinafter referred to as “Recommendations”) were released. Currently, China is among the nations with the highest number of patients suffering from Neuromyelitis Optica Spectrum Disorders (NMOSD) in the world. The release of the Recommendations not only helps to standardize and improve the quality of NMOSD diagnosis and treatment in China but will also have a profound impact on global NMOSD clinical practices.
The drafting and review of the Recommendations involved 23 renowned Chinese experts in neurology, radiology, and ophthalmology, all of whom possess extensive experience in administering Inebilizumab. These experts hail from various prestigious institutions, including the National Medical Center for Neurological Diseases (Huashan Hospital), the Neurology Branch of the Shanghai Stroke Society, several hospitals across the Yangtze River Delta region, as well as West China Hospital and Xiangya Hospital. Professor Qiang Dong, the Executive Director of the Neurology Department at Huashan Hospital affiliated with Fudan University, served as the chairman of the review meeting. Professor Chao Quan, the Chief Physician of the Neurology Department at Huashan Hospital affiliated with Fudan University, was the lead author. Additionally, Professor Bruce A.C. Cree and two other leading international experts in the NMOSD field also participated in the discussions on the Recommendations.
Release Ceremony for the “Expert Recommendations for the Clinical Practice of Treating Neuromyelitis Optica Spectrum Disorder With Inebilizumab”
Similar to other rare diseases, patients who suffer from NMOSD in China have long been caught in a dilemma where there is a “lack of medical resources and medication.” One issue is that many primary care physicians lack awareness about this rare disease, leading to misdiagnoses of many NMOSD patients. Another issue is that prior to the approval and launch of monoclonal antibody drugs, China mainly used traditional immunosuppressants for remission treatment. Although these treatments had some efficacy, it was still difficult to achieve the treatment goal of effectively controlling relapse.
In recent years, the approval of highly effective biologics, represented by inebilizumab, and their inclusion in national health insurance have significantly improved accessibility to drugs for NMOSD patients in China. This development has also resulting in valuable findings on the clinical practice of anti-CD19 monoclonal antibodies in the NMOSD field both in China and globally.
The use of monoclonal antibody drugs in China has been low in the past, and grassroots hospitals lack experience in the application of such drugs. As a first-in-class drug, inebilizumab has been on the market for a short time, and primary care physicians require more detailed and relevant clinical practice guidelines to standardize the application of such drugs.
Professor Chao Quan provides an on-site interpretation of the “Expert Recommendations for the Clinical Practice of Treating Neuromyelitis Optica Spectrum Disorder With Inebilizumab”
To address the aforementioned issues, the Shanghai Stroke Society initiated the compilation and review work for the “Expert Recommendations for the Clinical Practice of Treating Neuromyelitis Optica Spectrum Disorder With Inebilizumab”. The Recommendations cover common questions regarding the application population, timing of use, pre-medication assessment, methods of use, post-medication monitoring, how to switch medications, monotherapy and combination therapy, the possibility of discontinuation, safety management, and application of inebilizumab in special populations, providing a theoretical basis for its safe and effective clinical application.
Professor Chao Quan stated that the Shanghai Stroke Society will continue to update and refine the “Recommendations” based on more real-world evidence, with the hope that China's practical experience in the field of NMOSD will influence the world in the future.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
